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Association between rapidly progressive glomerulonephritis and the
properdin factor BfF and different HLA-D region products. Frequencies
of the HLA antigens ABC, DR and MT, as well as of the properdin
factor alleles were determined in 24 unrelated patients presenting with
immune complex mediated idiopathic rapidly progressive glomerulone-
phritis (RPGN) type II. As in Goodpasture syndrome (RPGN type I
with pulmonary hemorrhage), a significant association with the B-cell
alloantigen HLA-DR 2 was demonstrated (relative risk for HLA-DR 2
positive individuals was 3.54; P < 0.01). In addition a marked increase
of the HLA specificity MT 3 was shown, which is supposed to belong to
an antigen system of a second HLA-D region locus. The highest relative
risk of 14.67 (P < 0.00001), however, was calculated for all patients
carrying the BfF phenotype. Increased numbers of patients positive for
HLA-DR 2 and -MT 3, as well as BfF suggested immune response genes
or disease-related mutations on different haplotypes responsible for a
MHC (major histocompatibility complex) associated predisposition of
RPGN type II.
Association entre Ia glomerulonéphrite rapidement progressive et le
BIT du facteur de Ia properdine et les produits des différentes regions
HLA.D. Les frCquences des antigénes HLA, ABC, DR et MT, ainsi que
les alleles du facteur de la properdine ont éte déterminées chez 24
malades non consanguins ayant une glomerulonephrite rapidement
progressive idiopathique mCdiée par des immunescomplexes (RPGN)
de type II. Comme dans le syndrome de Goodpasture (RPGN de type I
avec hémorragie pulmonaire), une association significative avec l'al-
loantigene cellulaire B HLA-DR 2 a Cté démontrCe (le risque relatif pour
des individus positifs a HLA-DR 2 était 3,54; P < 0,01). En plus, une
augmentation marquee de Ia spécificité HLA-MT 3 a eté montrée,
laquelle est supposée appartenir a un système antigénique d'un second
locus HLA-D. Le risque relatif Ic plus élevC, 14,67 (P < 0,00001),
cependant, Ctait calculé pour tous les malades porteurs du phenotype
BfF. Les nombres augmentés de malades positifs pour HLA-DR 2 et-
MT3, comme pour BfF suggeraient une réponse immune de genes ou de
mutations induites par Ia maladie sur différents haplotypes responsables
d'une MHC (complexe principal d'histocompatibilité) associés a Ia
predisposition a une RPGN de type II.
Rapid progression to renal failure in some patients with
nephritis of acute onset was first observed by Voihard and Fahr
[1] in 1914 and later on described as a characteristic symptom of
rapidly progressive glomerulonephritis (RPGN) [2]. This dis-
ease mainly affects adults of a mean age of 50 years [3]. It
causes glomerular damage either as a primary (idiopathic)
kidney disease or occurs in association with systemic, infec-
tious, or drug allergic diseases [41.
Idiopathic RPGN is histologically characterized by exten-
sive, obliterating crescent formations within the Bowman's
space of the glomeruli. Three subsets of this disorder have been
identified with immunostaining: Linear deposits of IgG and less
often of C3 along the glomerular basement membrane (GBM)
are demonstrated in idiopathic RPGN of type I (anti-GBM
disease), whereas a granular staining pattern of IgG and/or 1gM,
as well as C3 is found mainly within the mesangial capillary wall
of type II [3, 5]. The third form of idiopathic RPGN shows no
apparent deposition of immunoglobulins [6].
Different immunological mechanisms are thought to underly
this primary glomerular disorder, since patients with idiopathic
RPGN of type I produce anti-GBM antibodies, whereas circu-
lating immune complexes are detected in the second form of
this disease. Recently, Goodpasture syndrome, which presents
as an anti-GBM disease accompanied by pulmonary hemor-
rhages, has been reported to show a strong association with the
antigen HLA-DR 2 of the human major histocompatibility
complex (MHC) [7]. This observation suggests that genetic
factors contribute to abnormal immune responsiveness and may
be involved in the pathogenesis of this kidney disease.
In this study HLA phenotypes of patients with idiopathic
RPGN of type II were determined to evaluate the influence of
the MHC on a genetic predisposition of this disorder. Particu-
larly the relationship between disease susceptibility and differ-
ent HLA-D region products, as well as the HLA-linked proper-
din factor (Bf) alleles was investigated in view of presumed
immune response genes mapping within the MHC system.
Methods
Patients. Twenty-four unrelated Caucasian patients with the
clinical symptoms of idiopathic RPGN (type II) were investigat-
ed. The diagnosis of the immune complex-mediated idiopathic
RPGN (type II) was verified by histological evaluation of renal
biopsies in all patients. As the typical pathomorphological
manifestation, crescent formations in all glomeruli were demon-
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strated in all kidney sections. In addition granular deposits of
IgG, and/or 1gM were observed in all kidney biopsy specimens
analyzed either by immunofluorescence studies or immunoper-
oxidase stainings. In four patients IgA was also found in the
glomeruli. Deposits of C3 were detected in 11 kidney biopsy
specimens.
Ten patients were females with a mean age of 44,4 years (14
to 72 years) and 14 were males with a mean age of 47.6 years (22
to 76 years). None of these patients presented with pulmonary
symptoms as a sign of an underlying Goodpasture syndrome.
Anti-GBM antibodies were not detected in the sera of all
patients. Secondary RPGN due to systemic lupus erythemato-
sus was excluded by the lack of anti-DNA antibodies in the sera
of all patients, as well as by the absence of further organ
involvements. No clinical signs of Wegener granulomatosis or
malignoma as another cause of secondary RPGN were detected
by extensive physical examination of the patients. Further-
more, the clinical investigation of all patients did not reveal a
history of drugs related to the onset of this disease. HLA
antigens of all patients were investigated and compared with
HLA phenotypes of a local control group of 125 normal
European Caucasians.
HLA -ABC, -DR, and -MT tissue typing. HLA-ABC antigens
were determined on peripheral blood lymphocytes according to
the standard microlymphocytotoxicity assay of the National
Institutes of Health [8] with locally well characterized anti-
HLA antisera defining all known HLA-ABC specificities.
HLA-DR and -MT typing was performed on B-lymphocytes in a
modified microlymphocytotoxicity assay with prolonged incu-
bation times for the antibody (1 hr) and the complement phase
(2 hr) [9]. A local anti-HLA-DR, -MT antiserum set was used
which included the best antisera of the 8th International Histo-
compatibility Workshop for the definition of the HLA-DR
specificities 1 - 10 and of the HLA-MT antigens 1 - 3. B-
lymphocytes were enriched from peripheral blood lymphocytes
by filtration through nylon wool columns as previously de-
scribed [91.
Properdin factor B (Bf) determination. The Bf alleles were
determined by starch gel electrophoresis as reported previously
[10].
Statistical analysis. The frequencies of the HLA-ABC, -DR,
and -MT antigens as well as the Bf alleles were calculated in the
patient group. They were compared with the HLA antigen
frequencies of our local control group of 125 normal European
Caucasians. Differences between patient and normal group
were statistically evaluated by x2 analysis with Yates correc-
tion. The relative risk to develop idiopathic RPGN (type II) was
calculated according to the method of Svejgaard and Ryder
[11].
Results
HLA-ABC, -DR, -MT typing results given in Table 1 showed
that the frequency of distinct HLA alleles in 24 investigated
patients with idiopathic RPGN (type II) was increased com-
pared with their incidence in a local population of 125 normal
European Caucasians.
In particular, a statistically significant higher frequency of the
antigen HLA-DR 2 was observed in the patient than in the
control group (Table 2). Of the patients 62.5% were found to be
positive for this antigen, whereas only 32.0% of the normal
Table 1. HLA-ABC, -DR, -MT antigens and Bf-phenotypes in 24
patients with idiopathic RPGN type II
HLA-phenotype Bf-
phenotypesPatient A B Cw DR MT
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2, 3
3,w24
1,2
2, w32
11, w32
28, —
2,—
1, w32
2,3
1,2
2, 26
2, w32
2, w24
11,w23
3,—
2,—
11, w24
2, —
2, —
2, 11
1, 3
1, 2
2, 3
2, w32
w44, w35
18,w60
7,w62
w37, w50
w35, w60
27, w60
w60,—
7, w44
7,w51
8, 18
7, w38
27, —
27, w35
7,w57
7,—
7,w62
5, 18
7, w62
14, wSl
w35, w57
8, w35
w53, w57
13, w35
w35, w63
4, —
3,—
1,4
6, —
3,4
1, 3
3,—
2, 3
—,—
7, —
7, 8
2, —
1, 4
2,7
1,—
3,7
—,
—
—, —
—, —
4, 7
4,7
—,
—
6, —
4, —
w6, 7
2,6
2,4
5, 7
2,4
4, 5
1,2
2,7
2,7
3,7
2, —
2, w8
5, —
2,7
2,—
2,4
2,4
2,4
5, w6
1, 5
3,4
2,7
2, 4
I, w6
2, 3
1,2
1,2
2, 3
1, 3
2, 3
1,—
1, 3
1,3
2, 3
I, —
1, 2
2, —
1,3
1,—
1,3
I, 3
I, 3
2, —
1, 2
2, 3
1, 3
1, 3
1, 2
FS
FS
F
F
FS
FS
FS
FS
F
F
S
F
S
F
FS
S
FS
S
ND
S
FS
S
FS
F
Abbreviation: ND, not done.
European Caucasians carried the HLA-DR 2 allele (x2 = 6.787;
P < 0.01). Thus an increased relative risk of 3.54 for HLA-DR 2
positive individuals was calculated. The influence of all other
defined HLA-DR alleles did not differ significantly from the
percentage of positive individuals found in the normal control
group.
Frequency analysis of the H LA-MT antigens, the most likely
products of a second serologically defined HLA-D region locus
[12, 13] showed an increase of the specificity HLA-MT 3 in the
patient group (Table 2). The specificity HLA-MT 3 was present
in 58.3% of the patients and in 29.6% of the normal European
controls. This difference in the HLA-MT 3 frequency was
statistically significant and reached a relative risk of 3.33 (P <
0.025) for all HLA-MT 3 positive individuals to develop idio-
pathic RPGN of type II. Furthermore, nine of 24 (37.5%)
patients carried an HLA phenotype positive for HLA-MT 3 as
well as HLA-DR 2, whereas only 13 of 125 (10.4%) normal
individuals were found to express both antigens (Table 2, x2 =
9.695; P < 0.005).
Among products of the HLA-ABC loci HLA-Cw 7 was
observed more frequently in the patients than in the normal
controls (Table 2). During the 8th International Histocompati-
bility Workshop linkage disequilibria of HLA-Cw 7 with HLA-
B 7 and -B 8 were described [14]. In the patient group both
individuals positive for HLA-B 8, as well as three of eight HLA-
B 7 positive persons carried the HLA-Cw 7 antigen. However,
four of six patients typed as HLA-Cw 7 positive showed also an
HLA-MT 3 positive phenotype.
The Bf allotypes of 23 patients analyzed are given in Table 1.
As blank alleles of the Bf locus have not been described seven
of 23 patients only typed as BfF were most likely to be
homozygous for this properdin factor allotype. The rare Bf
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Table 2. Frequencies of HLA antigens in 24 patients with idiopathic RPGN (type II) and in 125 normal European Caucasians as controls
HLA antigen
Patients(N = 24)
European
Caucasians
(N = 125)
Relative
risk x b
B7
Cw7
DR 1
DR 2
DR 3
DR4
DR 5
DRw6
DR 7
DRw8
DRw9
DRwIO
MT 1
MT 2
MT 3
DR 2- MT 3
33.3%
25.0%
12.5%
62.5%
8.3%
33.3%
20.8%
16.7%
29.2%
4.2%
—
—
70.8%
50.0%
58.3%
37.5%
28.0%
10.4%
20.8%
32.0%
17.6%
21.6%
28.8%
22.4%
20.0%
7.2%
4.8%
1.6%
72.0%
64.0%
29.6%
10.4%
1.29
3.04
0.54
3.54
0.43
1.81
0.65
0.69
1.65
0.56
—
—
0.94
0.56
3.33
5.17
0.080
2.657
0.435
6.787
0.686
0.959
0.304
0.126
0.533
0.010
—
—
0.017
1.131
6.163
9.695
NS
<0.15
NS
<0.01
NS
NS
NS
NS
NS
NS
—
—
NS
NS
<0.025
<0.005
a x2 is shown with Yates correction.
b The P value represents significance; NS, not significant.
allotypes BfF1 and BfS1 were not detected in the investigated
individuals with idiopathic RPGN type II. The BfF allele was
detectable in 17 of 23 patients (73.9%) compared to 36.9% in
normal controls (relative risk 4.85; x2 = 11.387; P < 0.001). The
calculated relative risk for the presumed BfFF homozygous
individuals was thus 14.67 (x2 = 38.588; P < 0.00001; Table 3
[15]). Analysis of the relationship between the Bf alleles and
HLA antigens showed that 11 of 14 HLA-MT 3 positive and 11
of 15 HLA-DR 2 positive individuals with idiopathic RPGN
type II carried the BfF allele.
Discussion
The results of this study demonstrate a genetic predisposition
to develop idiopathic RPGN (type II) for individuals expressing
the properdin factor allotype BfF and the HLA-D region alleles
HLA-DR 2 and HLA-MT 3. An increased frequency of the
antigen HLA-Cw 7 also observed in the patient group can be
explained by the known linkage disequilibrium of this MHC
product with the HLA-B locus antigens HLA-B 7 and -B 8. The
shared association of Goodpasture syndrome (idiopathic
RPGN, type I) [7] and idiopathic RPGN type II with HLA-DR 2
points to common genetic factors influencing abnormal immune
responses.
A similar relative risk for individuals carrying HLA-MT 3 or
-DR 2 suggests that the MT specificity may be as important as
the HLA-DR antigen for an inherited susceptibility of idiopathic
RPGN (type II). Recently, MT antigens have been claimed to
represent surface molecules controlled by MHC genes distinct
from, but closely linked to the HLA-DR locus [12, 13]. For
HLA-DR 2 a strong linkage disequilibrium with HLA-MT 1, but
not with -MT 3 has been demonstrated during the 8th Interna-
tional Histocompatibility Workshop [16]. HLA-DR 2 and -MT 3
are therefore most likely to occur on different haplotypes in the
analyzed patient group, although genotypes could not be deter-
mined in this study. This assumption is supported by the
observation that all HLA-DR 2 positive patients expressed
HLA-MT 1 in addition. The significantly increased number of
patients positive for HLA-DR 2, as well as HLA-MT 3,
Table 3. Bf phenotypes in 23 patients with idiopathic RPGN (type II)
and in 656 normal controls
Bf
phenotypes
Patients Controls(N = 23) (N = 656)a
Relative
risk x2" f-k
S 6 (26.1%) 391 (59.6%) 0.24 8.946 <0.005
FS 10 (43.5%) 216 (32.9%) 1.57 0.690 NS
F 7 (30.4%) 19 (3.0%) 14.67 38.588 <0.00001
a Normal controls are shown [15] including the rare Bf phenotypes
SS1 (N = 15), FS1 (N = 2), SF1 (N = 8), and FF1 (N = 5).b x2 is shown with Yates correction.
The P value represents significance, NS, not significant.
suggests that gene complementation plays an important role in
the manifestation of idiopathic RPGN, type II. A similarly
elevated frequency of the antigen HLA-MT 3 might have been
present in the reported 15 HLA-DR 2 positive patients with
Goodpasture syndrome due to a linkage of this MT product with
the determined HLA-DR 4 or -DR 7 positive phenotypes [71.
The highest relative risk to develop idiopathic RPGN of type
II was calculated for individuals expressing the BfF allotype.
Several disease associations of Bf alleles already have been
described [17]. In particular, a high incidence of the rare BfF1
allele was found in another kidney disorder, the idiopathic
membranous nephropathy [18]. Nothing is known whether the
properdin factor genes are involved directly in the pathogenesis
of these diseases as part of the complement system, or whether
they serve as markers for closely linked disease susceptibility
genes. Thus, in patients with idiopathic RPGN of type lithe
BfF allele could belong to a set of disease markers including the
associated HLA-D region products on an extended haplotype
which was maintained in the population due to cross-over
suppression of a human t-like locus on chromosome 6 and is
characterized by disease-related gene mutations [17]. Family
studies will be needed to delineate the haplotypes found among
the patient group and to evaluate which part of the MHC
influences abnormal immune responses and is involved in the
pathogenesis of this disease.
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